Darbepoetin Administration in Term and Preterm Neonates.
Darbepoetin Administration in Term and Preterm Neonates.
复制标题
DOI：
10.1016/j.clp.2015.04.016
复制
发表时间：
2015-09
影响因子：
2.1
通讯作者：
Ohls RK
中科院分区：
文献类型：
--
作者：
Patel S;Ohls RK
使用促红细胞生成剂促红细胞生成素（Epo）作为早产儿和足月儿的红细胞生长因子已经研究了20多年。最近的研究已经评估了Darbepoposide（Darbe，长效ESA）的红细胞生成作用和潜在的神经保护作用。我们回顾了最近Darbe在足月儿和早产儿中的临床试验。足月儿和早产儿的临床研究报告了Darbe的显著红细胞生成用途以及ESA给药后的神经保护作用，并在早产儿研究中报告了改善的神经发育结局。Darbe在减少或消除新生儿输血以及预防和治疗足月儿和早产儿脑损伤方面显示出巨大的前景。
The use of the erythropoiesis stimulating agent erythropoietin (Epo) has been studied as a red cell growth factor in preterm and term infants for over 20 years. Recent studies have evaluated Darbepoetin (Darbe, a long acting ESA) for both erythropoietic effects and potential neuroprotection. We review recent clinical trials of Darbe in term and preterm infants. Clinical studies in term and preterm infants have reported significant erythropoietic uses for Darbe as well as neuroprotective effects following ESA administration, and improved neurodevelopmental outcomes have been reported in studies of preterm infants. Darbe shows great promise in decreasing or eliminating transfusions in neonates, and in preventing and treating brain injury in term and preterm infants.